An interventional study of Trigeminal Nerve Stimulation in Generalized Anxiety Disorder, sponsored by Dr. Rafael Freire. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Dr. Rafael Freire · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Generalized Anxiety Disorder with a site in Canada — 7 open to participants now, 11 under way, none of them phase 3. Generalized Anxiety Disorder · Canada.
Among the 50 studies in Generalized Anxiety Disorder with a site in Canada, this one is the 37th largest by planned enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2024, is one of 32 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 47th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →7 of the 50 studies in Generalized Anxiety Disorder with a site in Canada are open now. Recruiting first, the newest first:
Claudio N Soares · Sites in Canada
Ages 18–60
Fraser Health · Sites in Canada
Ages 19+
Queen's University · Sites in Canada
Ages 18–65
Universite du Quebec en Outaouais · Sites in Canada
Ages 14–18 · Healthy volunteers
Vincent Agyapong · Sites in Canada
Ages 16–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 88 Generalized Anxiety Disorder studies recruiting now, 32 (36%) set no upper age limit and 54 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 63 across the 45 interventional studies, 380 across the 5 observational. Of the 34 that completed or were terminated, 3 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 50 have an industry lead sponsor. The 10 most frequent:
Dr. Rafael Freire is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Dr. Rafael Freire has 2 studies filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Generalized Anxiety Disorder with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06856161Fraser HealthA Novel Blood Test as a Biomarker in Mental Health | 2027-03-15 |
| NCT05574140McGill University Health Centre/Research Institute of the McGill University Health CentreBreathinG-induced Myocardial and Cerebral Perfusion in Anxiety Disorders | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 50 studies in Generalized Anxiety Disorder with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a feasibility study for trigeminal nerve stimulation (TNS) in patients with treatment-resistant generalized anxiety disorder (TR-GAD). Ten participants will receive TNS for 8 weeks as an augmentation strategy to pharmacological treatment for generalized anxiety disorder (GAD).
Results from this study will inform a randomized controlled trial to be conducted in the future.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Trigeminal nerve stimulation will occur by placement of electrodes (1.25" silver electrodes Bio-Flex BF4, Biotens/Vermed, Buffalo, New York, USA) bilaterally on the V1 branches of the trigeminal nerve (CNV) located on the forehead. Current will be generated from the EMS 7500 stimulator (TENS Products, Inc., Granby, CO) (Class II medical device) and will be set to a level that is clearly perceptible by each patient (i.e. tingling sensation) but not uncomfortable or painful. Current level will be determined for each patient at baseline and will likely be between 4-6 milliampere (mA). Active stimulation will occur at 120 Hz with a 250 μs pulse width and with a duty cycle of 30 seconds on to 30 seconds off.
Device: Trigeminal Nerve Stimulation
Active trigeminal nerve stimulation
Incidence of treatment-emergent adverse events
Monitor participants for treatment-emergent adverse events and serious adverse events.
Time frame: Throughout the study, 8 weeks
Incidence of treatment-emergent side effects measured with the NSEC
Monitor participants for minor treatment-emergent side effects measured with the Neurostimulation Side-Effect Checklist (NSEC). NSEC is a list of 31 possible side effects from neurostimulation or from antidepressants. Each item is rated from 0 (absent) to 3 (severe).
Time frame: Baseline visit, 4-week visit and 8-week visit.
Response to treatment defined by CGI-I score below 3
Response to treatment, which will be defined as a score of 1 or 2 on the Clinical Global Impression - Improvement (CGI-I) scale. CGI-I is a clinician administered one-item clinical scale rated from 1 (very much improved) to 7 (very much worse). Not assessed would confer score 0.
Time frame: 4-week visit and 8-week visit.
Remission defined by CGI-S score below 3
Remission will be defined as a score of 1 or 2 on the Clinical Global Impression - Severity (CGI-S) scale. CGI-S is a clinician administered one-item clinical scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Not assessed would confer score 0.
Time frame: 4-week visit and 8-week visit.
Change in anxiety severity measured by CGI-S
Changes in scores for CGI-S by comparing the scores in each visit. CGI-S is a clinician administered one-item clinical scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Not assessed would confer score 0.
Time frame: Baseline visit, 4-week visit and 8-week visit.
Change of anxiety symptoms measured with GAD-7
Changes in scores for Generalized Anxiety Disorder 7-item scale (GAD-7) by comparing the scores in each visit. GAD-7 is a self-rated 7-item scale, each item is rated from 0 (not at all) to 3 (nearly every day).
Time frame: Baseline visit, 4-week visit and 8-week visit.
Change of anxiety symptoms measured with PSWQ
Changes in scores for Penn State Worry Questionnaire (PSWQ) by comparing the scores in each visit. PSWQ is a self-rated 16-item scale, each item is rated from 1 (not at all typical of me) to 5 (very typical of me).
Time frame: Baseline visit, 4-week visit and 8-week visit.
Change of anxiety symptoms measured with BAI
Changes in scores for Beck Anxiety Inventory (BAI) by comparing the scores in each visit. BAI is a self-rated 21-item scale, each item is rated from 0 (not at all) to 3 (severely - it bothered me a lot).
Time frame: Baseline visit, 4-week visit and 8-week visit.
Plan to share: No
Started Jan 2024 (actual). Primary completion is estimated for Mar 2026, 25 months after the start.
Of 176 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 25 months is below that.
Counting every sponsor, half of 185 studies reached it within 28 months; a quarter within 15 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Generalized Anxiety Disorder →
Dr. Rafael Freire